Abstract Search

ea0094oc2.2 | Endocrine Cancer and Late Effects | SFEBES2023

¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic/inoperable phaeochromocytomas and paragangliomas and focus on the impact of genetic variations in SDHx mutation on treatment outcomes – A single centre retrospective analysis of experience at an ENETS Centre of Excellence

Mansukhbhai Shekhda Kalyan , Armeni Eleni , Hayes Aimee , Navalkissoor Shaunak , Mandair Dalvinder , Xu Yiwang , Yu Dominic , Quigley Ann-Marie , Gnanasegaran Gopinath , Toumpanakis Christos , Caplin Martyn , Khoo Bernard

Introduction: Metastatic phaeochromocytomas (PCC) and paragangliomas (PGL), collectively known as metastatic PPGL (mPPGL), represent uncommon neuroendocrine tumours for which no standardized treatment guidelines exist. The emerging therapeutic modality employing 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) has exhibited favourable tolerability in the management of these patients.Methods: In this...

0 shares

Endocrine Abstracts

BiosciAbstracts

Endocrine Abstracts

177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic/inoperable phaeochromocytomas and paragangliomas and focus on the impact of genetic variations in SDHx mutation on treatment outcomes – A single centre retrospective analysis of experience at an ENETS Centre of Excellence

BiosciAbstracts